Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119901 | 1.00 | BRD4 (0.63) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL2811918 | 1.00 | BRD4 (0.63) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL15684270 | 1.00 | BRD4 (0.63) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL3826960 | 0.89 | BRD4 (0.53) | BRD4MAPTPOLBRECQLGAA | |
| Glycerin SCHEMBL3843494 | 0.86 | MAPT (0.51) | BRD4MAPTPOLBRECQLGAA | |
| Triethylene Glycol SCHEMBL1362131 | 0.83 | BRD4 (0.51) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL14372529 | 0.83 | BRD4 (0.63) | BRD4MAPTPOLBRECQLSMN1; SMN2 | |
| SCHEMBL13803892 | 0.83 | BRD4 (0.63) | BRD4MAPTPOLBRECQLSMN1; SMN2 | |
| Itaconate SCHEMBL2524622 | 0.82 | BRD4 (0.50) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL29138381 | 0.82 | BRD4 (0.46) | BRD4MAPTPOLBRECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| CN-115551841-A | Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor | 爱杜西亚药品有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | BRD4 1279/4885MAPT 3493/4885POLB 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.